Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Schiffmann

Showing results (81-90 of 225) with videos related to

Pageof 23
Sort By:
Clinical Chemistry|September 13, 2005
Decreased asialotransferrin in cerebrospinal fluid of patients with childhood-onset ataxia and central nervous system hypomyelination/vanishing white matter diseaseAdeline Vanderver, Raphael Schiffmann, Margaret Timmons, et al.
Journal of Lipid Research|September 2, 2020
Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse modelSiamak Jabbarzadeh-Tabrizi, Michel Boutin, Taniqua S Day, et al.
Drug Design, Development and Therapy|June 17, 2016
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapyOzlem Goker-Alpan, Nicola Longo, Marie McDonald, et al.
Biochimica Et Biophysica Acta|July 20, 2010
Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseasesFanny Mochel, Nadège Boildieu, Julie Barritault, et al.
Journal of Neuropathology and Experimental Neurology|December 18, 2012
More than hypomyelination in Pol-III disorderAdeline Vanderver, Davide Tonduti, Genevieve Bernard, et al.
European Journal of Human Genetics : EJHG|April 1, 2004
Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patientsAnne Fogli, Raphael Schiffmann, Lynne Hugendubler, et al.
Human Genetics|July 26, 2005
Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patientsLiraz Kantor, Heather P Harding, David Ron, et al.
The Journal of Pediatrics|June 24, 2008
Cognitive outcome in treated patients with chronic neuronopathic Gaucher diseaseOzlem Goker-Alpan, Edythe A Wiggs, Michael J Eblan, et al.
BMC Women'S Health|October 28, 2004
Screening for known mutations in EIF2B genes in a large panel of patients with premature ovarian failureAnne Fogli, Fernande Gauthier-Barichard, Raphael Schiffmann, et al.
Orphanet Journal of Rare Diseases|April 11, 2025
Gaucher disease type 3 from infancy through adulthood: a conceptual model of signs, symptoms, and impacts associated with ataxia and cognitive impairmentRaphael Schiffmann, James Turnbull, Robert Krupnick, et al.
Pageof 23

Showing results (81-90 of 225) with videos related to

Sort By:
Pageof 23
Clinical Chemistry|September 13, 2005
Decreased asialotransferrin in cerebrospinal fluid of patients with childhood-onset ataxia and central nervous system hypomyelination/vanishing white matter diseaseAdeline Vanderver, Raphael Schiffmann, Margaret Timmons, et al.
Journal of Lipid Research|September 2, 2020
Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse modelSiamak Jabbarzadeh-Tabrizi, Michel Boutin, Taniqua S Day, et al.
Drug Design, Development and Therapy|June 17, 2016
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapyOzlem Goker-Alpan, Nicola Longo, Marie McDonald, et al.
Biochimica Et Biophysica Acta|July 20, 2010
Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseasesFanny Mochel, Nadège Boildieu, Julie Barritault, et al.
Journal of Neuropathology and Experimental Neurology|December 18, 2012
More than hypomyelination in Pol-III disorderAdeline Vanderver, Davide Tonduti, Genevieve Bernard, et al.
European Journal of Human Genetics : EJHG|April 1, 2004
Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patientsAnne Fogli, Raphael Schiffmann, Lynne Hugendubler, et al.
Human Genetics|July 26, 2005
Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patientsLiraz Kantor, Heather P Harding, David Ron, et al.
The Journal of Pediatrics|June 24, 2008
Cognitive outcome in treated patients with chronic neuronopathic Gaucher diseaseOzlem Goker-Alpan, Edythe A Wiggs, Michael J Eblan, et al.
BMC Women'S Health|October 28, 2004
Screening for known mutations in EIF2B genes in a large panel of patients with premature ovarian failureAnne Fogli, Fernande Gauthier-Barichard, Raphael Schiffmann, et al.
Orphanet Journal of Rare Diseases|April 11, 2025
Gaucher disease type 3 from infancy through adulthood: a conceptual model of signs, symptoms, and impacts associated with ataxia and cognitive impairmentRaphael Schiffmann, James Turnbull, Robert Krupnick, et al.
Pageof 23